New drug cocktail shows promise for tough head and neck cancers

NCT ID NCT03818061

Completed Disease control Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a combination of two drugs, atezolizumab and bevacizumab, in 33 adults with advanced head and neck cancer that had worsened after chemotherapy. The goal was to see if the combo could shrink tumors or slow disease progression. Results may help guide future treatments for this hard-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab (Tecentriq) and Bevacizumab (Avastin)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced head and neck cancer that has stopped responding to chemotherapy.
What could go wrong: This is a small, early-phase study with only 33 participants, so results may not apply to everyone. The combination may cause side effects like high blood pressure or immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck neoplasm Head and Neck Neoplasms head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK NEOPLASMS

Contacts and locations

Locations

Centre Antoine Lacassagne

Nice, 06189, France
Centre Henri Becquerel

Rouen, 76038, France
Centre Léon Bérard

Lyon, 69373, France
Centre Paul Strauss

Strasbourg, 67065, France
Clinique Mutualiste de l'Estuaire

Saint-Nazaire, 44606, France
Institut Claudius Regaud

Toulouse, 31059, France
Institut Curie

Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.